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ABSTRACT  
   
Background: Meticulous rectal cancer surgery is imperative in the treatment of rectal cancer. 
Total mesorectal excision (TME) is required to decrease local recurrence and improve overall 
survival after surgical resection of rectal cancer.  
Purpose: The purpose of this study is to evaluate a surgeon’s perception of TME by asking 
surgeons to predict the pathology results of surgeries they perform prior to obtaining pathology 
data.  
Hypothesis: It is hypothesized that the majority of surgeons are accurately perceiving and 
performing complete TMEs, during rectal cancer resections. We would like to quantify the 
accuracy of the surgeon's perception of complete total mesorectal excisions. 
Objectives:  
(1) To determine if a surgeon's perception of completeness of excision correlates with 
pathology data. If so, to quantify the accuracy of the surgeon's perception of complete 
TMEs.  
 
(2) To determine which factors affected a surgeon's ability to obtain a complete resection.  
 
 
Patients and methods: A prospective study on all adult rectal cancer patients in Saskatchewan 
from August 2014 to August 2016, including a total of 16 patients.  
Results: Data analysis was performed using a kappa agreement calculation. The calculation was 
performed using a cross tabulation of surgeon prediction of TME as nearly complete or complete 
versus pathology results of nearly complete, complete or incomplete. There were a total of 16 
cases and specimens analyzed. The data demonstrated a kappa value of 0.067 which corresponds 
with a p-value of 0.733, suggesting poor and non-significant correlation between surgeon 
prediction of completeness of total mesorectal excision and pathology result.  
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INTRODUCTION 
 Rectal cancer is a common cause of morbidity and mortality amongst Canadians. 
Optimally, rectal cancer is diagnosed and treated early in the disease course to improve 
outcomes. Often the treatment of rectal cancer is multifaceted combining a multidisciplinary 
approach amongst primary care physicians, screening programs, radiology, surgical oncology, 
medical oncology, radiation oncology, pathology, and other health care professionals. Surgery 
remains one of the mainstays of treatment for rectal cancer. The surgical approach, utilizing total 
mesorectal excision (TME), has been shown to decrease local recurrence and improve overall 
survival (Washington et al, 2013).  
This study aims to investigate the mesorectal excisions performed for rectal cancer 
surgeries across four hospitals within Saskatchewan, Canada. The purpose of this study is to 
evaluate a surgeon’s perception of total mesorectal excision by asking surgeons to predict the 
pathology results of surgeries they perform prior to obtaining pathology data.  
The study involved two phases of data collection. First, survey data was collected from 
surgeons and second, patient information was collected along with pathology data. It is 
hypothesized that the majority of surgeons are accurately perceiving and performing complete 
mesorectal excisions, during rectal cancer resections. We would like to quantify the accuracy of 
the surgeon's perception of complete mesorectal excision. Therefore, there are two main 
objectives of this study. The first objective is to determine if a surgeon's perception of 
completeness of excision correlates with pathology data. If so, the goal is to quantify the 
accuracy of the surgeon's perception of complete TMEs. The second objective is to determine 
which factors may have affected a surgeon's ability to obtain a complete resection. 
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LITERATURE SURVEY  
 CANADIAN CANCER STATISTICS 
Cancer remains a large cause of morbidity and mortality amongst Canadians. Statistics 
from the Canadian Cancer Society for 2015 state that approximately 2 in 5 Canadians will 
develop cancer in their lifetime and approximately 1 in 4 Canadians will die of cancer (Canadian 
Cancer Society, 2015). Furthermore, for 2015 it is estimated that 196,900 people will be 
diagnosed with cancer and 78,000 Canadians will die of cancer with the year (Canadian Cancer 
Society, 2015). As of 2015, colorectal cancer is the 2
nd
 most common cancer in Canadian males 
and 3
rd
 most common cancer in Canadian females, representing 13.9% and 11.5% of new cases, 
respectively (Canadian Cancer Society, 2015). In 2015, it is estimated that there will be 25,100 
new cases of colorectal cancer in Canada, with 14,000 male patients and 11,100 female patients 
(Canadian Cancer Society, 2015).  
 
Table 1.1:  Estimated new cases for the most common cancers in Canada, 2015  
(Canadian Cancer Society, p. 34, 2015) 
Out of all the estimated new cases of colorectal cancers diagnosed in Canada, a total of with 770 
of these patients are estimated to be from Saskatchewan, with 430 male patients and 340 female 
patients (Canadian Cancer Society, 2015). 
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Table 1.2:  Estimated new cases for selected cancers by sex and province in Canada,  
  2015  
(Canadian Cancer Society, p. 36, 2015) 
This equates to 1 in 14 Canadian males and 1 in 16 Canadian females being diagnosed with 
colorectal cancer during their lifetime (Canadian Cancer Society, 2015). Thus, many patients 
will also die from colorectal cancer. The percent distribution of estimated cancer deaths by sex 
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for 2015, show 12.4% of male deaths and 11.5% of female deaths will result from colorectal 
cancer (Canadian Cancer Society, 2015).  
 
Figure 1.1:  Percent distribution of estimated cancer deaths in Canada for 2015  
(Canadian Cancer Society, p. 39, 2015) 
Therefore, colorectal cancer is a relatively common malignancy amongst the Canadian 
population. The significance of understanding how to optimize treatment of colorectal cancer, is 
consequently, of utmost importance.  
 COLORECTAL CANCER SCREENING 
Currently, there have been many colorectal screening programs implemented across 
Canada to identify patients with premalignant polyps and colorectal cancers. In Saskatchewan, 
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the Saskatchewan Screening Program for Colorectal Cancer (SPCRC) is a program developed by 
the Saskatchewan Cancer Agency to screen for colorectal cancer (Saskatchewan Cancer Agency, 
2015). Fortunately, the mortality rates for colorectal cancer, in both women and men have been 
steadily declining in Canada from 1986 until 2015. The following tables illustrate this for both 
females and males.  
 
Figure 1.2: Female mortality rates for selected cancers in Canada, 1986-2015  
(Canadian Cancer Society, p. 42, 2015) 
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Figure 1.3: Male mortality rates for selected cancers in Canada, 1986-2015  
(Canadian Cancer Society, p. 41, 2015) 
Both figure 1.2 and 1.3 clearly demonstrate that age-standardized mortality rates for colorectal 
cancers have declined from 1986 to 2015. This is attributed to a combination of factors 
including: improved screening, risk factor reductions, and enhanced treatments (Canadian 
Cancer Statistics, 2015). 
RECTAL CANCER AS A PROPORTION OF COLRECTAL CANCER 
Colorectal cancer can occur anywhere along the colon (right colon, transverse colon, left 
colon, or sigmoid colon) or rectum (upper rectum, middle rectum or lower rectum). Therefore, 
rectal cancer is a proportion of all the colorectal cancers. However, in Canadian statistics, these 
cancers are presented as a conglomerate under colorectal cancers as an inclusive group.  
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INTRODUCTION OF Mesorectal Excision 
Many factors have been studied with respect to optimizing rectal cancer surgery. One 
large area of interest was introduced in the 1980’s, which involved a surgical technique called 
total mesorectal excision. Heald et al were the first to describe and introduce the operative 
principle of total mesorectal excision in 1982 (Heald, Husband, and Ryall, 1982). Previously, 
rectal cancer surgery was performed with manual blunt dissection in the pelvis. “[A] 
conventional resection… may be characterized as blunt dissection within the pelvis along 
variable, i.e. non-anatomical planes. The failure to perform a standardized procedure, i.e. 
anatomical dissection along definable planes, leads to an incomplete resection of the primary 
rectal tumour along with any regional mesorectal spread” (Havenga, 1999, p. 372). The 
following illustration demonstrates the correct and incorrect dissection planes of total mesorectal 
excision.   
 
Illustration 1.1:  Mesorectal excision. A) Correct Dissection, B) Incorrect Dissection  
(http://www.surgicalcore.org/popup/182828) 
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According to Parfitt and Driman, who reference Cecil et al and Faerden et al, this was initially 
shown by MacFarlane who published follow up data on Heald’s practice:  
MacFarlane, who studied with Heald, subsequently published prospective follow-
up data based on Heald’s practice, the result of which was greatly increased 
interest in TME technique. The results of these studies showed that TME was a 
superior surgical modality for the treatment of rectal cancer, as local recurrence 
rates were reduced from 30-40% without TME to <5% with TME. Subsequent 
studies have confirmed this and it is now generally accepted that a local 
recurrence rate of <10% should be expected if proper TME techniques are 
employed (Parfitt and Driman, 2006, p. 849).  
 
Therefore, the technique to obtain a total mesorectal excision has been widely adopted by all 
surgeons performing colorectal surgery. “Total mesorectal excision is considered the gold 
standard for rectal cancer surgery” (Lin, 2011, p. 537).  
DEFINITION OF MESORECTAL EXCSION 
Various definitions of a total mesorectal excision have been developed. A concise 
definition of total mesorectal excision is defined by the University of Toronto, Surgical 
Oncology Manual, as follows: total mesorectal excision involves “excising the rectum en bloc 
with its blood and lymphatic supply (mesorectum)” (Yasser et al, 2012. p. 216). The following 
diagram illustrates a lateral view of the total mesorectal excision dissection plane.  
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Illustration 1.2:   Mesorectal excision.  
(http://www.cancernetwork.com/cancer-management/colon-rectal-and-anal-cancers/page/0/3) 
This illustration depicts the surgical margin when removing a rectal cancer with its 
encompassing mesorectum, thus resecting the surrounding blood vessels, lymph nodes, 
lymphatic drainage system, mesentery, and mesorectal fascia. Of note, some sources differentiate 
total mesorectal excision (TME) from partial mesorectal excision (PME) based on the location of 
the anatomical resection of the upper, middle, or lower rectum:  
A mesorectal excision can be total (TME) or partial (PME) in extent. The TME 
refers to complete excision of the mesorectum down to the pelvic floor and is 
indicated for carcinoma of the middle and lower third of the rectum. In the case 
of PME, although circumferentially the excision is performed in the same way as 
TME, the mesorectum is transected at a right angle to the rectal wall at a distance 
of 5 cm beyond the gross distal edge of the tumour; PME is sufficient for 
treatment of carcinomas of the upper third of the rectum (Parfitt and Driman, 
2006, p. 849).  
 
This definition is used in some, but not all sources. Many sources simply refer to only TME 
generally and do not mention PME specifically. Therefore, although this distinction is made, for 
the purposes of this thesis, the term TME has been used for all tumours of the rectum.  
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 One study evaluated showed that a Quality Assessment Instrument could be used to 
assess Total Mesorectal Excisions. This study was performed by Simunovic et al, in 2014, where 
they tested the interrater reliability (IRR) of a product analysis tool called the Total Mesorectal 
Excision- Quality Assessment Instrument (TME-QA). They found that this method of 
assessment surgical specimens “may provide rapid and relevant feedback to surgeons about their 
technical performance” (Simunovic et al, 2014, p. 2274). Basically, if there is a standardized way 
to report TME specimens, with good interrater reliability, then this could be effect for showing 
“good internal consistency and IRR when the TME-QA is used by pathologists ” (Simunovic et 
al, 2014, p. 2274). This study shows that standard reporting of TME specimens is essential, in 
order to ensure accuracy of reporting.  
SURGICAL TECHNIQUE OF MESORECTAL EXCISION 
Optimal surgical resection with meticulous operative technique is imperative to rectal 
cancer surgery. "The quality of the surgical technique is a key factor in the success of surgical 
treatment for rectal cancer, both in the prevention of local recurrence and long-term survival" 
(Washington et al, 2013, p. 16). Obtaining a total mesorectal excision involves a “surgical 
technique [that] entails precise sharp dissection within the areolar plane outside (lateral to) the 
visceral mesorectal fascia to remove the rectum. This plane encases the rectum, its mesentery, 
and all regional lymph nodes and constitutes Waldeyer’s fascia” (Washington et al, 2013, p. 16). 
Thus, “[t]otal mesorectal excision (TME) involves sharp dissection in the plane that separates the 
visceral mesorectal fascia from the parietal pelvic fascia” (Marr et al, 2005, p. 74). One study, 
examined 32 cadavers in detail to identify the various fascial planes that encompassed a total 
mesorectal excision. This study found that, the “autonomic nerves and lateral rectal ligament can 
be distinguished as the landmark to judge the different planes. The correct surgical plane of the 
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posterior dissection is conducted between the visceral fascia and parietal fascia, and anterolateral 
dissection is conducted between the vesicohypogastric fascia and parietal fascia” (Lin et al, 
2011, p. 537). Various descriptions of the surgical technique of total mesorectal excision have 
been described. A thorough description is provided by Heald et al as follows:  
The essence of the surgical technique is the painstaking development under direct 
visualization of the avascular plane between the mesorectum and the surrounding 
parietal tissues right down to the distal extremities of the pelvis. The excised 
specimen thus includes the whole posterior, distal, and lateral mesorectum out to 
the plane of the inferior hypogastric plexuses, which are carefully preserved. 
Anteriorly, it includes the intact Denonvilliers fascia and the peritoneal reflection. 
The characteristic bilobed encapsulated appearance of the intact mesorectum 
posteriorly and distally reflects the contours of the pelvic floor and the midline 
anococcygeal raphe. The ideal specimen has a smooth unbroken surface like that 
of a lipoma. This is achieved by meticulous sharp dissection in the avascular 
areolar plane surrounding the mesorectum. Finally, great importance is attached 
to preventing implantation by the use of sterile wash to wash out the rectal stump 
below a clamp before the anorectum is divided and the pelvis itself, before and 
after the division. “Heald et al, 1998, p. 895).  
This description is very detailed and comprehensive, and thus was included for reference 
regarding surgical technique of total mesorectal excision.  
 TYPES OF SURGERIES, TO PERFORM MESORECTAL EXCISION  
Surgery has evolved to include several options for the operative management of rectal 
cancer. “In the recent [two] decades, improvements have been achieved in the outcomes of rectal 
cancer surgery with the advances in surgical techniques as well as adjuvant therapy. 
Abdominoperineal resection, the previous gold standard treatment of rectal cancer, has been 
regarded as unnecessary in most patients with rectal cancer and more patients can now be treated 
with sphincter-saving surgery” (Law et al, 2004, p. 260). Various surgical approaches, depending 
on the location of the tumour have been developed for removing the mesorectum with the rectal 
cancer.  
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Illustration 1.3:  Types of Rectal Cancer Surgery.   
(https://www.cancersa.org.au/information/a-z-index/surgery-for-bowel-cancer) 
Illustration 1.3 depicts the anatomical resection differences between an Anterior Resection (AR), 
Ultra-Low Anterior Resection (Ultra-LAR), and Abdominoperineal resection (APR). These 
surgical approaches are clearly defined by the University of Toronto, Surgical Oncology Manual 
(Yasser et al, 2012), and are described hereafter. An anterior resection (AR) often involves 
excision of a rectosigmoid or upper rectal cancer, and is defined as, “sharp mesorectal resection 
down to 5 cm past leading edge” of the tumour. Another surgery, used for resection of upper 
rectal or middle rectal cancer is the low anterior resection, which is defined as, “a sphincter 
preserving TME and anastomosis below the peritoneal reflection.” If the entire rectum is 
removed and if an anastomosis is performed, this may be referred to as a proctectomy with 
coloanal anastomosis (CAA) which may or may not involve J-pouch reconstruction.  Lastly, if 
the entire rectum is removed with an abdominoperineal resection (APR), this is defined as, 
“TME en bloc with the anus” and this includes a permanent end colostomy (Yasser et al, 2012, p. 
216). In addition, the surgeon may elect to perform a stoma to divert the fecal stream and protect 
a healing anastomosis where the proximal and distal bowel are reconnected. “The creation of a 
stoma should effectively divert the faecal stream from a healing anastomosis, thereby mitigating 
the consequences of anastomotic failure” (Peeters, 2005, p. 214). A surgeon may also elect to 
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perform the surgery using an open technique, or laparoscopic technique.  “Laparoscopic TME is 
a feasible but technically demanding procedure (12% conversion rate)” (Morino, 2003, p. 335). 
Initial concerns regarding the oncologic safety of laparoscopic surgery have been studied and 
show equivalency to open procedures. “Laparoscopic TME is feasible and safe. The laparoscopic 
approach to the surgical treatment of operable rectal cancer does not seem to entail any 
oncologic disadvantages” (Leroy et al, 2004). In summary, there are many surgical procedures 
used to operate on rectal cancer and to obtain total mesorectal excisions. These various 
techniques have been summarized, as they will be recorded amongst the patient data collected 
within this study.  
 SURGICAL MARGINS 
 In addition to obtaining a complete total mesorectal excision for rectal cancer surgeries, it 
is ideal to obtain negative resection margins. The margins reported in the American Joint 
Committee on Cancer (AJCC)/ Union for International Cancer Control (UICC) Tumour Node 
Metastasis (TNM) 7
th
 edition staging system include: closest margin, circumferential (radial) or 
mesenteric margin (CRM), proximal margin, and distal margin (Washington et al, 2013). Of 
note, “[t]umour involvement of the proximal bowel margin is unusual, and distal intramural 
tumour extension more than 2 cm from the primary lesion is uncommon” (Wibe et al, 2002, 
p327). In contrast to the proximal and distal margins, the CRM remains as a vital prognostic 
indicator. According the College of American Pathologist guidelines:  
The circumferential (radial) margin represents the adventitial soft tissue margin 
closest to the deepest penetration of tumor and is created surgically by blunt or 
sharp dissection of the retroperitoneal or subperitoneal aspect respectively… A 
positive circumferential (radial) margin in rectal cancer increases the risk of 
recurrence by 3.5-fold and doubles the risk of death from disease… The 
circumferential (radial) margin is considered negative if the tumor is more than 1 
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mm from the inked nonperitonealized surface but should be recorded as positive 
if tumor is located 1 mm or less from the nonperitonealized surface because local 
recurrence rates are similar with clearances of 0 to 1 mm (Washington et al, 
2013).  
 
Therefore, the CRM plays a role in overall patient prognosis in addition to TME. This was also 
demonstrated in a study by Hung-Hsin et al, where they demonstrated that a circumferential 
resection margin of ≤ 1 mm adversely affected cancer-specific 5-year survival rates (0% vs. 
75.8%), local recurrence (15.4% vs. 1.8%) and distant metastasis (61.5% vs. 13.4%), compared 
to patients with negative CRMs, respectively (Hung-Hsin et al, 2013). Another study showed 
that “Positive CRM, higher T-stage, and higher N-stage were risk factors for [local recurrence]” 
(den Dulk et al, 2007, p. 89). Therefore, surgical margins play a role in local recurrence.  
 LOCAL RECURRENCE 
 The main argument for performing TME is to decrease local recurrence and increase 
survival of rectal cancer patients (Carlsen et al 1998, Leroy et al 2004). According to Marsh et al, 
“[l]ocal recurrence (LR) is defined as recurrent disease in the pelvis, including recurrence at the 
site of the bowel anastomosis or in the perineal wound” (as cited in Wibe, 2002, p. 859). A major 
goal in the treatment of rectal cancer is to reduce local recurrence, because the development of a 
local recurrence has substantial implications for the patient’s postoperative course.  
Local recurrence after surgery for rectal cancer is a disaster for the patient. In 
addition to severe pain, there may be interference with circulation and nerve 
function of the legs, ureteric obstruction, intestinal obstruction, fistulation, 
infection and discharge. Cure at this stage is seldom possible and the disease 
often takes a prolonged and excruciating course. Palliative treatment is not 
always successful and may in addition have severe side-effects (Arbman et al, 
1996, p. 375).  
 
Many factors affect the development of local recurrence. “Positive lymph nodes, N2 disease, 
lymphatic vascular invasion, and perineural invasion were independent significant risk factors 
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for local recurrence” (Enker et al, 1997, p. 715).  Performing TME is a modifiable risk factor to 
decrease local recurrence and increase survival of rectal cancer patients.   
Previous research has been done on the prognostic significance associated with the Total 
Mesorectal Excision. Martling et. al. did a study, in 2004, which they analyzed “the prognostic 
value of surgeons’ and pathologists’ assessments of tumour clearance in patients with primary 
rectal cancer.” In this study, 1550 patients were studied prospectively, where both the surgeons 
and pathologist reported if the tumour clearance was ‘complete’, ‘uncertain’, or ‘incomplete.’ Of 
note, in “patients assessed as having a complete surgical clearance, tumour recurrence developed 
in 33.3 per cent. For patients with an uncertain or incomplete clearance the recurrence rate was 
59.5 and 61 per cent respectively (P <0.001)”. The authors therefore concluded that, 
“[a]ssessments of tumour clearance were of strong prognostic value in relation to outcome. 
When the surgeon or pathologist was uncertain, or there was disagreement about the 
completeness of clearance, the risk of recurrence was similar to that among patients in whom an 
incomplete resection had been performed” ((Martling et al, 2004, p. 1040). This study shows that 
the pathologist’s and the surgeon’s prediction of TME results has an important implication in 
prognosis for the patient.  
PHYSIOLOGICAL OUTCOMES AFTER TME 
Not only is total mesorectal excision imperative for oncologic outcomes, it is also 
essential for physiologic outcomes, which are impacted by surgery and other factors like 
radiation therapy. Specifically, autonomic nerve preservation (ANP) during total mesorectal 
excision has been described as an integral part of rectal cancer surgery to preserve sexual 
function (Enker et al, 1997). “Preservation of the intact superior and inferior hypogastric 
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plexuses and hypogastric nerves safeguards sexual and bladder function” (Brown et al, 2004, p. 
432). Of note, the addition of radiotherapy to TME adds additional morbidity. “Although 
preoperative short-term radiotherapy for rectal cancer results in increased local control, there is 
more long-term bowel dysfunction in irradiated patients than in patients who undergo TME 
alone” (Peeters et al, 2005, p. 6199). Therefore, autonomic nerve preservation during TME is 
important because the addition of radiation can also impact nerve function.  
 COMBINED MODALITY, MULTIDISCIPLINARY TREATMENT 
Initially, surgery alone was found to be insufficient in the treatment of rectal cancer. “The 
standard surgical approaches of abdominoperineal (AP[R]) resection or anterior resection (AR) 
have produced disappointing results, both in local control and in overall survival. This has 
prompted the development of adjuvant strategies using radiotherapy, chemotherapy, or both to 
improve outcomes” (Heald et al, 1998, p. 894). Research advances in the last few decades have 
found that surgical management of rectal cancer is optimized with a multidisciplinary approach 
combing surgery, chemotherapy, and radiotherapy. Many studies have found that radiotherapy 
has a beneficial effect in reducing local recurrence. One study by Kapiteijn examined 1748 
patients who were randomly assigned to macroscopically complete local resection surgery, with 
or without radiotherapy. “The rate of local recurrence at two years was 2.4 percent in the 
radiotherapy-plus-surgery group and 8.2 percent in the surgery-only group (P < 0.001).” 
(Kapiteijn et al, 2001, 638). Therefore, the authors concluded that, “[s]hort-term preoperative 
radiotherapy reduces the risk of local recurrence in patients with rectal cancer who undergo a 
standardized total mesorectal excision (Kapiteijn et al, 2001, 638). Additionally, it has been 
shown in the literature that chemoradiotherapy (CRT) in addition to TME aids in obtaining 
negative resection margins. “Capecitabine/oxaliplatin before synchronous CRT and TME results 
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in substantial tumor regression, rapid systematic response, and achievement of RO resection” 
(Chau et al, 2006, p. 668). Therefore, improving rectal cancer outcomes is multifaceted as it 
involved multidisciplinary treatment.  
 RESEARCH ADVANCES 
Ideally, the treatment of rectal cancer is optimized. In a paper from 1999, there were 
many obstacles standing in the way of optimizing rectal cancer treatment. At that time, the 
authors noted, “Quality control, training and the education of surgeons in practice, as well as 
standardization of other involved disciplines, i.e. pathological evaluation, remain the major 
problems to be addressed in the future” (Havenga et al, 1999, p. 373). Major strides in rectal 
cancer surgery, pathology, and treatment have been made since 1999. Ideally, we will continue 
to advance with ongoing research in the rectal cancer field.  
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RATIONALE AND OBJECTIVES 
 As mentioned, rectal cancer is life threatening condition that impacts patients within the 
province of Saskatchewan. Numerous previous studies have shown that the local recurrence and 
overall survival is impacted by the surgical excision of rectal cancer.   The standard treatment, 
when resecting rectal cancers with curative intent, is to obtain a total mesorectal excision in order 
to reduce local recurrence and improve overall survival.  
Currently, rectal cancer surgery within the province of Saskatchewan has remained 
largely unstudied. We are interested in investigating the surgeon's perception of completeness of 
excision after performing each rectal cancer surgery and correlating this with the patient's 
pathology data. The research question in this study aims to identify how accurate a surgeon’s 
perception is in predicting the results of mesorectal excisions as complete, nearly complete or 
incomplete. Furthermore, we would like to ask surgeons to identify factors that affect their 
ability to achieve a total mesorectal excision. Surgeons can identify factors that made the 
dissection of the TME more difficult or less difficult in an open ended fashion. The pathology 
specimen will then be analyzed by the pathologist and will be reported as complete, nearly 
complete, or incomplete.  
Statistical analysis will then be performed to assess the accuracy of a surgeon’s 
prediction of the TME results using Kappa stastics. This will identify how accurate a surgeon’s 
perception is, with respect to predicting the Total Meosrectal Excision as incomplete, nearly 
complete, or complete.  
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MATERIALS AND METHODS  
 The study design involves a chart review to collect patient data and a survey to ask 
surgeons questions regarding a patient’s surgery. This study was developed prospectively, 
largely to evaluate a surgeon’s perception of rectal cancer surgeries with respect to Total 
Mesorectal Excision (TME). The benefits of performing TME surgery well known in the 
literature. However, asking the surgeon to predict their own pathology results required 
prospective data collection and analysis prior to release of pathology data.  
 There are many possible definitions of the rectum. For the purposes of this study, the 
anatomical definition of the rectum to be used within the study had to be defined. The definition 
selected for the purposes of this study was developed by the College of American Pathologists, 
from the 2013 guidelines (Washington et al, 2013). This definition is as follows:  
Definition of Rectal cancers:  based on CAP (College of American Pathologists) Guidelines 
(2013): 
The rectum, with approximate dimensions measuring 12 cm long from the anal verge, constitutes 
three anatomical segments:  
-Upper third: covered by peritoneum on anterior and lateral surfaces 
 -Middle third: covered by peritoneum only on anterior surface 
 -Lower third: has no peritoneal covering 
The transition from sigmoid to rectum is marked by the fusion of the tenia coli of the sigmoid to 
form the circumferential longitudinal muscle of the rectal wall approximately 12 to 15 cm from 
the dentate line. The rectum is defined clinically as the distal large intestine commencing 
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opposite the sacral promontory and ending at the anorectal ring, which corresponds to the 
proximal border of the puborectalis muscle palpable on digital rectal examination. When 
measuring below with a rigid sigmoidoscope, it extends 16 cm from the anal verge.  
This definition of the rectum clearly differentiates the upper, middle, and lower rectum. 
Furthermore, it includes different anatomical characteristics including peritoneum, tenia coli, 
dentate line, sacral promontory, anorectal ring and puborectalis muscle; all of which are 
important in delineating the rectum both surgically and pathologically. Lastly, this definition 
includes the definition of the rectum from the endoscopic perspective, with using the rigid 
sigmoidoscope.  
 Types of Total Mesorectal Excision (TME) had to be defined for the purposes of this 
study as well. Mesorectal excisions can be classified as incomplete, nearly complete and 
complete.  
 
Illustration 1.4:  Types of Mesorectal Excision: A) Complete B) Nearly complete C) 
Incomplete  
(http://onlinelibrary.wiley.com/doi/10.1002/cncr.24387/pdf) 
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Of note, the anterior and posterior view of a complete mesorectum can be differentiated grossly 
based on the appearance. The normal anatomical landmark of a midline cleft, also known as a 
“rectal buttocks,” is seen on the posterior aspect of the mesorectum and is characteristic of a 
complete mesorectal excision. This is depicted in the following illustration provided by Parfitt 
and Driman (Parfitt & Driman, p. 851, 2006): 
 
Illustration 1.5:  Types of Mesorectal Excision:  
A) Complete – Anterior view B) Complete – Posterior view C) Incomplete 
(the arrow points to a deep defect exposing the muscularis propria) 
(http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994509/#!po=35.1852) 
 
Each of these types of mesorectal excision is classified based on their gross macroscopic 
pathology, examined in the pathology department. The College of American Pathologists clearly 
defined what defines each type of mesorectal excision, as follows (Washington et al, 2013):  
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Mesorectal Excision: 
Incomplete 
-Little bulk to the mesorectum 
-Defects in the mesorectum down to the muscularis propria 
-After transverse sectioning, the circumferential margin appears very irregular 
Nearly Complete 
-Moderate bulk to the mesorectum 
-Irregularity of the mesorectal surface with defects greater than 5 mm, but none extending to the 
muscularis propria 
-No areas of visibility of the muscularis propria except at the insertion site of the levator ani 
muscles 
Complete 
-Intact bulky mesorectum with a smooth surface 
-Only minor irregularities of the mesorectal surface 
-No surface defects greater than 5 mm in depth 
Each rectal cancer in Saskatchewan is reported pathologically in a standard reporting format 
used by all pathologists. This is the current total mesorectal excision definition used for the 
American Joint Committee on Cancer (AJCC)/ Union for International Cancer Control (UICC) 
Tumour Node Metastasis (TNM) 7
th
 edition staging system used in current pathology reporting 
in Saskatchewan.  
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The study design initially involved a one-year prospective research project, which was 
subsequently extended to include a second year of data collection to maximize patient accrual.  
 This study was approved by the Biomedical Research Ethics Review Board for both the 
University of Saskatchewan and the University of Regina. Ethics approval was granted in August 
of 2014 and subsequent data collection was initiated. The ethics was renewed in August 2015 to 
include a second period of data collection over another year.  
  The goal of this study was to include several hospitals within Saskatchewan to maximize 
surgeon and patient data accrual and to include patients from several hospitals in Saskatchewan. 
Furthermore, this broad-based approach was used to attempt to represent the majority of rectal 
cancer patients treated in Saskatchewan. A total of four hospital sites were included in the study 
within different health regions. Each hospital site was de-identified and kept confidential within 
the study. Hospital site names were coded for the purposes of data collection and data analysis.  
Two surveys were issued to each participating surgeon. The first survey was an intake 
survey of each participating surgeon to be completed once at the beginning of the study. The 
second survey was a patient related survey. This second survey was to be completed by the 
performing surgeon each time a rectal cancer is resected.  
Informed consent by participating surgeons was required for this study. General surgeons 
were identified amongst four hospitals within Saskatchewan by their central departmental 
offices. Surgeons were subsequently invited to participate in the study by email invitation. There 
were no exclusion criteria for the surgeon's participation. Surgeons, who agreed to participate in 
the study, subsequently completed an online survey. This survey was provided through the Fluid 
Surveys tool provided by the University of Saskatchewan. Consent was obtained by completion 
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of reading an informed consent form within the survey. Each surgeon was informed of the 
potential risks and potential benefits of the study. These risks and benefits were reviewed and 
approved by the research ethics board. Risks and benefits identified by REB:  
Potential Risks:  
 -All reasonable steps will be made to ensure patient privacy and is protected 
within this study and patient confidentiality is maintained.  
-All surgeons will be de-identified and their identity will be confidential in the 
study results.  
-Surgeons will have access to their own results and to the study results after study 
completion.  
Potential Benefits:  
-Identification of the number of rectal cancer patients treated in Saskatchewan  
-Identification of the number of Total Mesorectal Excisions performed  
-Identification of Surgeon's perceptions of Rectal Cancer Surgeries. 
-May develop areas of future study - e.g. questions may arise from research 
regarding future research in Rectal Cancer.  
All of these potential risks and benefits were clearly stated on the consent form. Furthermore, 
each surgeon was informed that the results of the study were to be kept confidential. Surgeons 
were informed, patient and surgeon data would be kept confidential, each surgeon’s data was to 
be de-identified, and no surgeon’s name would be published or revealed in any study 
publications. Surgeons provided consent by stating they agree to participate in the study and they 
would subsequently indicate this by pressing a button within the online survey. Each surgeon 
was informed that they had the right to withdrawal from the study at any time.  
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Each surgeon was asked demographic information (name, email, hospital of practice, 
years of practice), and training background (year completed medical school, year completed 
surgical training, and if any fellowship or subspecialty training).  Each surgeon was also given 
the opportunity to request results of the study once they were available. For the purposes of the 
study data collection, each surgeon’s name de-identified and assigned a surgeon identification 
code number, to code each surgeon’s name on the survey and within the data analysis. Once 
surgeons enrolled in the study, data collection regarding rectal cancer surgeries commenced.  
Data collection involved two phases of collection. The first phase of data collection 
involved obtaining patient-specific surgery data from the individual participating surgeons. The 
second phase of data collection involved collecting patient data from a chart review and 
pathology report review.  
Consent was waived for patient participation within the study. Patients were identified for 
inclusion within the study from operative slates provided at each hospital site. It was not possible 
to identify or contact patients preoperatively. Often, contact information is obtained for patients 
on the day of admission of surgery. It was agreed upon, along with the research ethics review 
board, that obtaining consent for data collection from patients post-operatively may induce 
anxiety regarding TME results and pending pathology reports. Therefore, this was treated like a 
quality improvement initiative where consent is not required to analyze patient data. Patient data 
was to be kept confidential. Each patient was given a study identification code for data collection 
and analysis. The only patient data collected on a study code form included the patient’s medical 
record number (MRN) for hospital chart access and the patient’s personal health number (PHN) 
for pathology data access. Data collection did not include the patient’s name or date of birth as 
this was not essential for patient identification for the purposes of this study.  
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Patient inclusion criteria were: adults, age greater than or equal to 18 years of age, male 
and female patients, and patients who underwent rectal cancer resection surgery. All of these 
patients must have been treated with surgical resection at one of the four hospital sites included 
within the study. Patient exclusion criteria were: children less than 18 years old and those with 
pathology specimens that may have been sent out of province for analysis where data is not 
available. 
 Once a rectal cancer patient was identified on the operative slate of a consenting surgeon, 
patient MRN and PHN was recorded on the study patient identification code form. Once surgery 
was completed, the operative report was reviewed to confirm the patient was treated with 
resection for a rectal cancer. A survey, Patient Related Questionnaire of Participating Surgeons, 
was then sent to the surgeon regarding the patient’s surgery. This survey was sent electronically 
via email using the University of Saskatchewan Fluid Surveys tool. The first page of the survey 
form included pre-entered information on the month, date, year, procedure performed, and 
surgeon identification code. Surgeons were sent the survey shortly after the surgical procedure, 
ideally within 24-48 hours of the surgery. Surgeons received an email requesting completion of 
the survey. Each email also contained the pre-entered information on the month, date, year, 
procedure performed, and surgeon identification code. The email also had direct website link to 
the specific Fluid Survey created for each surgical patient. No identifying patient information 
was included on the email or the online survey. In the event that more than one surgical 
procedure for rectal cancer was performed in one day, an optional entry on the first page of the 
survey included the time of the procedure, so that surgeon could differentiate two or more 
possible patients receiving rectal cancer surgeries on the same day. As discussed with the 
research ethics board, if a surgeon could not remember which patient was operated on, the plan 
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was for the research personnel to contact the surgeon by phone call to provide patient 
identification so that the surgeon could complete the appropriate survey. However, this 
contingency plan was not necessary over the course of the study, as surgeons were able to 
identify from the month, day, year, and procedure performed, which patient a survey was 
referring to. If a surgeon was not able to complete a survey, a reminder email was sent to the 
surgeon within 72 hours of the initial survey invitation.  
 The study was designed to have the surgeon to complete the patient-specific survey prior 
to the release of pathology data. This would allow the surgeon to predict the pathology data prior 
to its release. The pathology report was generally released within 2-4 weeks post operatively.  
The Patient Related Questionnaire of Participating Surgeons asks questions about date of 
surgical procedure performed, confirmation that the surgery was performed for a rectal tumour, 
and the surgeon’s prediction of the mesorectal excision (complete, nearly complete, or 
incomplete).  Each surgeon was asked if the surgery was indeed performed for a rectal cancer 
(yes/no). Furthermore, each surgeon was asked if the surgery was performed with curative intent 
(yes/no). The surgeon was also asked to list possible factors that made the mesorectal excision 
more difficult or less difficult.  
To minimize the work load on the surgeon, the remaining patient data was collected by 
the research personnel. Patient data was accessed online from hospital based computers utilizing 
the Sunrise Clinical Manager electronic patient record. The patient data collection forms 
recorded information on sex, age, medical history, surgical history, body mass index if available, 
preoperative chemotherapy, preoperative radiotherapy, surgery performed, complications, 
estimated blood loss, preoperative pathology, and postoperative pathology. All of the rectal 
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cancer specimens were processed by the pathology departments as per standard practices. 
Pathology information collected includes tumour characteristics (type, location, size, and stage), 
TME classification, margin status, histologic characteristics (type, grade), microscopic tumour 
extension, lymphovascular invasion, perineural invasion, and type of polyp in which the rectal 
cancer arose. Additionally, data was collected on ancillary studies performed by the pathology 
department (special stains, microsatellite instability, immunohistochemistry for mismatch repair 
proteins, and mutational analysis). Also, if the patient received neoadjuvant chemotherapy or 
radiation prior to surgery, it was documented if a treatment effect was identified pathologically.  
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RESULTS  
 Surgeons at four hospital sites within Saskatchewan were invited to participate in this 
study. Approximately 25-30 surgeons were invited to participate. The goal number of surgeons 
to participate in the study was 5-10 surgeons, as a proportion of these surgeons do not practice 
rectal cancer surgeries within their general surgery practice. A total of 8 surgeons consented to 
participate and enrolled in the study across the province of Saskatchewan. Each surgeon was 
enrolled during the entire study period. There was no withdrawal of consent to participate in the 
study submitted by any of the participating surgeons.  
 Rectal cancer patients were enrolled starting when ethics approval was obtained on 
August 29, 2014. Patient enrolment continued into a second year of the study while ethics 
approval was extended until August 2016. Actual data collection continued until April 2016 and 
then ceased once research study goals of 10-15 enrolled patients were met.  
Surgical slates were examined among the hospital sites of the participating surgeons. 
When a rectal cancer resection surgery was identified on the operative slates, operative records 
were reviewed to ensure surgical resection was indeed performed for a rectal cancer. 
Subsequently, consenting surgeons were sent surveys regarding their prediction of the Total 
Mesorectal Excision pathology results.  
A total of 16 patients were enrolled in the study. Data was collected on each individual 
patient’s characteristics. The surgical procedure was recorded. Each surgeon was asked to 
confirm if the procedure was performed for a rectal cancer and if the procedure was performed 
with curative intent. All the surgeons stated that each patient was indeed diagnosed with a rectal 
cancer (100%, 16/16 patients). Furthermore, all the surgeons stated that each patient was treated 
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with a curative intent, and therefore no palliative resection procedures were performed (100%, 
16/16 patients). The following table summarizes all the procedures performed on the rectal 
cancer patients in this study.  
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Procedure Performed  
Procedure 
Performed  
for Rectal 
Cancer  
Procedure 
Performed 
with 
Curative 
Intent 
1 APR, Posterior Vaginectomy Yes Yes  
2 
Laparoscopic LAR with diverting 
ileostomy  Yes Yes  
3 
Laparotomy, LAR, Bilateral 
ureterolysis, Loop ileostomy Yes Yes  
4 Open LAR  Yes Yes  
5 
Exploratory Laparotomy, 
Adhesionolysis, APR Yes Yes  
6 Laparoscopic assisted APR Yes Yes  
7 Open APR  Yes Yes  
8 
Laparoscopic converted to open 
APR Yes Yes  
9 
Laparoscopic converted to open 
LAR with diverting loop 
ileostomy  Yes Yes  
10 Open APR  Yes Yes  
11 
Laparoscopic assister LAR with 
coloanal anastomosis and Loop 
Ileostomy Yes Yes  
12 
Laparoscopic assisted LAR and 
loop ileostomy  Yes Yes  
13 
LAR, End Colostomy, Right pelvic 
sidewall lymph node dissection  Yes Yes  
14 
Pelvic exenteration, LAR, 
cystoprostatectomy, ileal 
conduit, colostomy  Yes Yes  
15 
Laparoscopic assisted LAR, loop 
ileostomy, rigid sigmoidoscopy  Yes Yes  
16 APR Yes Yes  
Table 1.3:  Procedures performed for each enrolled patient in the study with 
confirmation from surgeons performing procedures that the procedures were 
performed for rectal cancers with curative intent. (Blue = APR, Light grey = LAR)  
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Pathology results were examined and collected for each enrolled patient. Data analysis of 
patient pathology data quantified the number of complete, nearly complete and incomplete total 
mesorectal excisions performed by each enrolled surgeon. The surgeon’s predicted TME result 
was compared to the actual TME result reported in the pathology report. Each patient’s result 
was analyzed to see if the predicted result correlated with the actual reported result.  
 
MESORECTAL EXCISION:  
 
Complete, Nearly Complete, Incomplete  
 
Surgeons Prediction of 
Mesorectal Excision  
Pathologic Mesorectal 
Excision  
1 Nearly Complete  Nearly Complete  
2 Nearly Complete  Complete  
3 Complete  Complete  
4 Complete  Complete  
5 Nearly Complete  Complete  
6 Complete  Nearly Complete  
7 Complete  Complete  
8 Nearly Complete  Complete  
9 Complete  Complete  
10 Complete  Complete  
11 Complete  Complete  
12 Nearly Complete  Incomplete 
13 Complete  Nearly Complete  
14 Complete  Complete  
15 Complete   Complete 
16 Complete  Incomplete  
Table 1.4:  Surgeon prediction of mesorectal excision versus pathological classification 
of mesorectal excision. (shaded = consistent result, unshaded = inconsistent result)  
A total of 9/16 surgeon’s predictions were consistent with the pathological results of 
classifications of mesorectal excisions. The surgeon’s prediction differed from the pathology 
report in 7/16 cases.  
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The Clinical Research Unit (CRU) at the University of Saskatchewan, under the 
supervision of Dr. June Lim, assisted with the data analysis. Their assistance was used to 
determine if there is a statistical correlation between the surgeon’s perception of completeness of 
mesorectal excision and the pathology data obtained from the study. As previously discussed 
with the CLR, this statistical analysis used Kappa statistics to analyze if there was statistical 
agreement between the categorical data. In essence, this allowed the study to evaluate how 
accurate surgeons are in predicting TME completeness in comparison to actual pathology data 
obtained for each patient.  
Each surgeon was asked in each patient-specific survey if there were any factors that 
made the total mesorectal excision more or less difficult to perform intraoperatively. This 
question was intentionally left open-ended to allow surgeons to decipher their own reasons for 
intraoperative factors that may have affected the dissection. The data was then further evaluated 
to assess if common factors were identified by the surgeons that made TME less or more difficult 
to attain.  
 
Factors that made Mesorectal Excision 
More Difficult 
Factors that made Mesorectal Excision 
Less Difficult 
1 
Previous hysterectomy with some 
adhesions requiring partial 
vaginectomy, Anterior Tumour 
especially considering previous surgery, 
Very friable fatty mesentery None Listed  
2 
Anatomical - bulky mesorectum, 
Narrow male pelvis  None Listed  
3 
Post-radiation fibrosis (radiation was 
>12 weeks before surgery), Bulky 
tumour as patient was unable to 
complete chemoradiation None Listed  
4 
Location of lesion at 7 cm, Uterus still 
present Female pelvis  
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5 
Inflammatory state continued after a 
significant adhesionolysis two nights 
previously  None Listed  
6 Patient obesity with BMI 38  None Listed  
7 None Listed 
Lack of neoadjuvant chemoradiation, 
Wide pelvis, Female  
8 
Body habitus - fat male with narrow 
pelvis  None Listed  
9 Body habitus - narrow male pelvis  None Listed  
10 
Male, overweight body habitus, post-
radiation  None Listed  
11 None Listed None Listed  
12 None Listed None Listed  
13 Bulky tumour None Listed  
14 Locally advanced tumour None Listed  
15 None Listed None Listed 
16 
Patient body habitus (narrow male 
pelvis, obese)  None Listed  
Table 1.5:  Factors listed by the surgeon, for each individual case, that made mesorectal 
excision more or less difficult.   
 
Each surgeon’s response to the question regarding factors that made the mesorectal excision 
more or less difficult was answered in an open-ended fashion. This allowed surgeons to answer 
in a non-biased manner, which factors they perceived affected their ability to obtain a complete 
mesorectal excision.  
 The data was analyzed using kappa agreement calculation. The calculation was 
performed using a cross tabulation of surgeon prediction of TME as incomplete, nearly complete 
or complete versus pathology results of incomplete, nearly complete, or complete. There were a 
total of 16 patients and 16 respective operative cases/specimens analyzed. This data is presented 
in the following table.   
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Table: 1.6: Cross Tabulation of Surgeon Prediction vs. Pathology 
 
Once the cross tabulation was performed, the data was further analyzed using the kappa 
agreement calculation. This is presented in the following table.  
 
Table: 1.7: Kappa Agreement Calculation of Surgeon Prediction vs. Pathology 
 
This data demonstrated a kappa value of 0.067 which corresponds with an approximate 
significance value of 0.733. This suggests poor and non-significant correlation between surgeon 
prediction of completeness of total mesorectal excision and pathology result as incomplete, 
nearly complete, or complete. 
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DISCUSSION   
 A surgeon’s perception of Total Mesorectal Excision has been largely unstudied to date. 
Surgeons often rely on many intraoperative cues to guide their surgical dissection. Various 
intraoperative findings including anatomical landmarks, tactile sensations, evidence of metastatic 
disease, and tumour factors guide intraoperative management.  
 This study pointedly asks surgeons which factors may have made it more or less difficult 
to obtain a TME. This question was intentionally left open ended so surgeons could list various 
factors which may have affected the TME resection in patient-specific scenarios. Various 
answers were obtained regarding these factors. Common reasons listed that made the mesorectal 
excision more difficult included: male pelvis, large body habitus, adhesions from previous 
surgeries, bulky tumour and post-radiation fibrosis. Common reasons listed that made the 
mesorectal excision less difficult included: female pelvis. In most cases, surgeons did not list any 
factors that made the mesorectal excision less difficult.  
 
Furthermore, we asked surgeons to predict their own patient’s TME results. We did 
hypothesize that surgeons would be relative accurate in predicting the TME results. Of note, 
there is absolutely no requirement for a surgeon to do this accurately. However, we expected that 
based on intraoperative findings and experience, each surgeon would be able to do this quite 
accurately.  
A total of 16 operative cases and 16 specimens were analyzed for this study. Of all these 
cases, the surgeon correctly predicted the pathology results in 9 out of 16 cases, or 56.25% of the 
time. Data analysis was performed using a kappa agreement calculation. The calculation was 
performed using a cross tabulation of surgeon prediction of TME as nearly complete or complete 
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versus pathology results of nearly complete, complete or incomplete. The data demonstrated a 
kappa value of 0.067. Basically, the kappa value is a measure of interobserver agreement 
between the pathologist and the surgeon. “Precision, as it pertains to agreement between 
observers (interobserver agreement), is often reported as a kappa statistic.” (Viera et al, 2005, p. 
360). Values can range from negative one to positive one. A value less than 0 represents an 
agreement that occurs less than chance. A value of 0 represents a poor agreement. A value of 
0.99 represents almost perfect agreement (Viera et al, 2005, p. 360). The kappa value in this 
study of 0.067, corresponds with a significance value of 0.733, suggesting poor and non-
significant correlation between surgeon prediction of completeness of total mesorectal excision 
and pathology result. 
Various limitations of this research study were identified during this project. One 
limitation of this study was that the pathology process of reporting specimens was not altered. 
Each pathology report was reported according to the College of American Pathologist guidelines 
that are currently used across the pathology departments. However, this study did not require that 
a specimen was read any differently than it otherwise would be. For example, some studies 
mandate that the specimen is double read by a second pathologist. Another example would be 
that a central review process could be set up to review the specimens in a standard centralized 
format for all patients in the study. This was not done, as our current health care resources for 
pathology processing would not allow for any further patholological processing as a result of this 
study to be carried out.  
It is possible, that a higher number of patients would be required to produce a significant 
result between surgeon prediction of TME and pathology results. However, is also possible that a 
surgeon’s perception may not allow them to accurately predict the TME pathology results. 
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Therefore, it is imperative to have an outside source, i.e. the pathologist, exam the specimen and 
determine if the TME is incomplete, nearly complete or complete. This objective assessment 
allows classification of the TME specimen.  
It is also possible, that surgeons are simply inaccurate in predicting the TME specimens. 
The surgeon is obligated to remove the cancer, whilst upholding the surgical principles of 
oncologic removal. However, there is no obligation of the surgeon to accurately predict the 
pathology result. It is possible, that intraoperative cues, such as tactile sensation, visual 
inspection, palpation, and other factors, are not sufficient to allow the surgeon to accurately 
predict the pathology results. This study emphasizes the need for an outside, objective 
pathologist to analyze the specimen and assess the total mesorectal excision.  
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CONCLUSION  
 In conclusion, rectal cancer remains a disease requiring multidisciplinary treatment with 
various combinations of chemotherapy, radiation, and surgery. Surgery with total mesorectal 
excision remains an integral part of treatment to ensure patients can be potentially cured with 
decreased local recurrence and improved overall survival.  
 Surgical practices in Saskatchewan regarding Total Mesorectal Excision have remained 
largely unstudied until recently. Our goal of this study was to evaluate a surgeon’s perception of 
Total Mesorectal Excision after each rectal cancer surgery was performed. All data was collected 
prior to pathology results being available. Therefore, each surgeon was asked without knowing 
actual pathology results if predicted the perceived Total Mesorectal Excision to be complete, 
nearly complete or incomplete. Most surgeons reported the TME as complete or nearly complete.  
 In addition, each surgeon was asked which operative factors may have made the 
dissection more or less difficult and thus could have influenced obtaining a Total Mesorectal 
Excision. Various answers were obtained regarding these factors. Common reasons listed that 
made the mesorectal excision more difficult included: male pelvis, large body habitus, adhesions 
from previous surgeries, bulky tumour and post-radiation fibrosis. Common reasons listed that 
made the mesorectal excision less difficult included: female pelvis. 
The data from this study included analysis on 16 enrolled patients. This demonstrated a 
kappa value of 0.067 which corresponds with an approximate significance value of 0.733, 
suggesting poor and non-significant correlation between surgeon prediction of completeness of 
total mesorectal excision and pathology result.  
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The element of knowledge translation and how this information will be passed on further 
is an important element of this research project. Each surgeon, who has requested their own 
results, will be provided with their own results and the final results of this research study. 
Furthermore, this project will be submitted for presentation at the University of Saskatchewan, 
Division of Surgery, Resident Research Day in 2017. Other venues to disseminate this 
knowledge will be applied for, in order to disseminate the results of this study in both Saskatoon 
and Regina, Saskatchewan. Furthermore, this data will be published in thesis format, and then 
will be submitted for publication in primary journal literature.  
There are several areas of possible future research. As this study did not examine all 
hospital sites within Saskatchewan, there is more information to be gained regarding the total 
number of rectal cancer surgeries performed within Saskatchewan per year. Furthermore, each 
surgeon had to consent to participate within this study. Therefore, there is unattained data from 
surgeons who did not consent for participation in this study. Further research could also be done 
in this area to see if higher numbers of enrolled patients could produce a significant result 
between surgeon’s prediction of TME and pathology results.  
It is also possible, that surgeons are simply inaccurate in predicting the TME specimens. 
The surgeon is obligated to remove the cancer, whilst upholding the surgical principles of 
oncologic removal. However, there is no obligation of the surgeon to accurately predict the 
pathology result. It is possible, that intraoperative cues, such as tactile sensation, visual 
inspection, palpation, and other factors, are not sufficient to allow the surgeon to accurately 
predict the pathology results. This study emphasizes the need for an outside, objective 
pathologist to analyze the specimen and assess the total mesorectal excision.  
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 PARTICIPANT INFORMATION AND CONSENT FORM  
 
Title of Study:   Surgical Practices in Saskatchewan: Researching a Surgeon's 
Perception of Total Mesorectal Excision 
 
Principal Investigator: 
 
 Dr. Gary Groot 
 General Surgeon 
 University of Saskatchewan 
 222 - 750 Spadina Crescent East   
 Saskatoon, SK, S7K 3H3  
 Tel:  (306) 653-3366 
 Fax:  (306) 653-8832 
 Email:  garygroot@gmail.com 
 
Student Researcher: 
 Dr. Julie Kickbush  
 General Surgery Resident  
 Supervisor: Dr. Gary Groot  
 Tel:  (306) 716-2803 
 Fax:  (306) 844-1522 
 Email:  jab177@mail.usask.ca 
 
_____________________________________________________________________________ 
 
INTRODUCTION  
You are invited to take part in this research study because you are a surgeon within the province 
of Saskatchewan who may be performing rectal cancer surgeries.  
 
Your participation is voluntary. It is up to you to decide whether or not you wish to take part in 
this study. If you decide to participate, you are still free to withdraw at any time and without 
giving any reasons for your decision.  Please take time to read the following information 
carefully. You can ask the study physicians to explain any information that you do not clearly 
understand. You may ask questions as you need.   
 
WHO IS CONDUCTING THE STUDY? 
This study is being conducted within the Clinical Investigator Program at the University of 
Saskatchewan by Dr. Gary Groot (General Surgeon, Principal Investigator) and Dr. Julie 
Kickbush (General Surgery Resident, Health Sciences Masters Student).  
 
This project is sponsored by the Division of General Surgery within the Clinical Investigator 
Program at the University of Saskatchewan. Neither the institution, nor any of the investigators 
or staff, will receive any direct financial benefit from conducting the study.  
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WHY IS THIS STUDY BEING DONE? 
Rectal cancer is life threatening condition that impacts patients within the province of 
Saskatchewan. Numerous previous studies have shown that the local recurrence and overall 
survival is impacted by the surgical excision of rectal cancer.   The standard treatment, when 
resecting rectal cancers with curative intent, is to obtain a total mesorectal excision in order to 
reduce local recurrence and improve overall survival.  
 
Currently, there is no pooled surgical and pathology data on rectal cancer surgeries within the 
province of Saskatchewan. Furthermore, research has not been conducted on perceptual factors 
of a surgeon that may affect rectal cancer excisions.  
 
We are interested in investigating how many rectal cancer surgeries are being performed, how 
many surgeons are performing rectal cancer surgeries, and how many total mesorectal excisions 
are being performed. We are also interested in investigating the surgeon's perception of 
completeness of excision after performing each rectal cancer surgery and correlating this with 
the patient's pathology data.  
 
WHO CAN PARTICIPATE IN THE STUDY? 
You are invited to participate in this study if you are surgeon within the province of 
Saskatchewan who is performing rectal cancer surgeries at Royal University Hospital 
(Saskatoon, SK), St. Paul's Hospital (Saskatoon, SK), Regina General Hospital (Regina, SK), 
and/or Pasqua Hospital (Regina, SK).  
 
WHAT DOES THE STUDY INVOLVE?  
This study is being done prospectively over one year (March 2014 - March 2015) to understand 
the rectal cancer surgeries currently done within the province of Saskatchewan. All data on rectal 
cancer patients will be collected at these sites. Data will be collected from surgeon surveys. 
Pathology data and patient data will also be collected by the study personnel for these same 
patients.  
 
After agreeing to participate in this study, you will be contacted by email to conduct an initial 
intake survey. Subsequently, after performing a rectal cancer surgery, you will be asked to 
complete a surgery-specific survey about the specific rectal cancer excision. All surveys are 
expected to take approximately 10-20 minutes to complete. This intact survey collects basic 
information about you including demographics, training, and practices.  
 
The patient-specific survey will be sent to you shortly after surgery is completed and ideally 
completed prior to pathology report released. Completion of this survey will take approximately 
5-15 minutes. This survey seeks to identify your perception of type of mesorectal excision, 
factors that made mesorectal excision more/less difficult. You will be asked to complete one 
patient-specific survey per patient operated on for Rectal Cancer. You may be asked to complete 
10-20 of these surveys. The higher volume surgeons will perform the most rectal cancer 
surgeries and thus will be asked to complete the greatest number of surveys.  
 
You need only answer those questions they are comfortable with answering. 
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CONFIDENTIALITY:  
In Saskatchewan, the Health Information Protection Act (HIPA) defines how the privacy of 
personal health information must be maintained so that patient privacy will be respected.  
 
Your confidentiality and patient confidentiality will be respected.  All surgeon and patient data 
will be coded and will be presented in a de-identified form in all publications of the data.  
No information that discloses your identity will be released or published without your specific 
consent to the disclosure. All data will be stored securely in the Principal Investigator’s office for 
five years after the study has been completed, after which time all hard copies and electronic 
copies will be permanently and confidentially destroyed.  
 
Research records and medical records identifying patients may be inspected in the presence of 
the Investigator or his or her designate and the University of Saskatchewan Research Ethics 
Board for the purpose of monitoring the research. However, no records, which identify patients 
or surgeons by name or initials, will be allowed to leave the Investigators' offices. The results of 
this study may be presented in a scientific meeting or published, but your identity will not be 
disclosed. 
 
POSSIBLE RISKS: 
If you choose to participate in this study, the main risk is the inadvertent releases of your 
personal information.  The researchers have taken measures to protect the privacy of your 
information and this risk is considered very small.  
 
POSSIBLE BENEFITS:  
If you choose to participate in this study, there will be no direct benefit to you. However, the 
information collected could help patients undergoing rectal cancer surgeries and may be 
informative to surgeons such as yourself who perform mesorectal excisions.  
 
RIGHT TO WITHDRAW:  
Your participation in this research is voluntary. You may withdraw from this study at any time. 
You do not have to provide a reason. There will be no penalty or loss of benefits if you choose to 
withdraw. If you choose to enter the study and then decide to withdraw later, all data collected 
about you during your enrolment will not be retained for analysis. Your right to withdraw from 
the study will apply until data collection is complete.  
 
WHAT WILL THE STUDY COST ME? 
You will not incur any costs or receive any payments for participating in the study.  
 
HOW CAN I OBTAIN MORE INFORMATION ABOUT THIS STUDY? 
If you provide your email address when you complete the intake survey, you will be emailed a 
summary of the results upon the conclusion of this study. 
 
WHO DO I CONTACT IF I HAVE QUESTIONS ABOUT THE STUDY?   
Thank you for considering participation in this study. If you have any questions or concerns, 
please feel free to contact either Dr. Gary Groot (306-653-3366 or garygroot@gmail.com) or Dr. 
Julie Kickbush (306-716-2803 or jab177@mail.usask.ca). . 
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This research project was reviewed and approved on ethical grounds through a harmonized 
review process by the University of Saskatchewan and Regina Qu’Appelle Health Region 
Research Ethics Boards.  Any questions regarding your rights as a participant may be addressed 
to that committee through the University of Saskatchewan Research Ethics Office at 306-966-
2975(out of town participants may call 1-888-966-2975). 
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 PARTICIPANT INFORMATION AND CONSENT FORM  
 
Title of Study:   Surgical Practices in Saskatchewan: Researching A Surgeon's 
Perception of  Total Mesorectal Excision  
 
- I have read the information in this consent form.  
 
- I understand the purpose and procedures and the possible risks and benefits of this study.  
 
- I was given sufficient time to think about it.  
 
- I had the opportunity to ask questions and have received satisfactory answers.  
 
- I understand that I am free to withdraw from this study at any time for any reason and the 
decision to stop taking part will not affect my future relationships or career.  
 
- I give permission to the use and disclosure of my de-identified information collected for 
the research purposes described in this form.  
 
- I understand that by clicking “I AGREE” I do not waive any of my legal rights.  
 
 
If you agree to participate in this study, please click “I AGREE” below. 
 
If you do not wish to participate in this study, you may close this tab in your browser to exit the 
survey. 
 
I AGREE (you will be taken to the intake survey on the next page) 
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Study Title: Evaluation of Rectal Surgery with respect to 
Total Mesorectal Excision in Saskatchewan 
Principle Investigators:  Dr. Gary Groot (Department of General Surgery: Saskatoon).  
   Dr. Julie Kickbush (General Surgery Resident: Saskatoon).  
Intake Questionnaire of Participating Surgeons: 
Demographics 
1. Name: 
i. First: 
ii. Last: 
2. Email: 
3. Hospital(s) of Practice: 
i. Location: 
ii. Location: 
iii. Location:  
4. Years in Practice: 
Training 
5. Training 
a. Medical Degree: 
1. Year Completed: 
b. Surgical Training: 
1. Year Completed: 
c. Subspecialty or Fellowship Training: 
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1. Yes/No:  
2. Fellowship Name:  
3. Year Completed: 
Research Questions:  
6. Would you be interested in receiving a copy of the final results of this study? 
1. Yes/No 
7. If you are interested in receiving a copy, how would you like the final results sent to you: 
i. Mail:  
a. Mailing Address: 
b. City: 
c. Province:  SK 
d. Postal Code:  _ _ _-_ _ _ 
ii. Electronic Copy by Email:  
a. Email Address:  
iii. Other: 
a. Fax:  (306) _ _ _-_ _ _ _ 
 
8. Would you like to receive your own personal results of the study?  
1. Yes/No 
9. If you are interested in receiving a copy, how would you like your personal results sent to you: 
i. Mail:  
a. Mailing Address: 
b. City: 
c. Province:  SK 
d. Postal Code:  _ _ _-_ _ _ 
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ii. Electronic Copy by Email:  
a. Email Address:  
iii. Other: 
a. Fax:  (306) _ _ _-_ _ _ _ 
  
55 
 
 
Study Title: Evaluation of Rectal Surgery with respect to 
Total Mesorectal Excision in Saskatchewan 
Principle Investigators:  Dr. Gary Groot (Department of General Surgery: Saskatoon).  
   Dr. Julie Kickbush (General Surgery Resident: Saskatoon).  
Patient-related Questionnaire of Participating Surgeons: 
Surgeon Demographics:  
1. Surgeon Identification Code: 
Patient Date of Procedure: 
2. Month: 
3. Day: 
4. Year: 
5. Time:  
Note to surgeons: If you are uncertain which patient this survey is for (e.g. if more than one 
surgery is performed in one day), please contact the research personnel by phone and we can 
confirm which patient this is for (Dr. Julie Kickbush: (306) 716-2803).  
Procedure: 
6. Procedure performed: 
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Definition of Rectal cancers:  based on CAP (College of American Pathologists) Guidelines (2012): 
The rectum, with approximate dimensions measuring 12 cm long from the anal verge, constitutes three 
anatomical segments:  
-Upper third: “covered by peritoneum on anterior and lateral surfaces” 
-Middle third: “covered by peritoneum only on anterior surface” 
-Lower third: “has no peritoneal covering” 
“The transition from sigmoid to rectum is marked by the fusion of the tenia coli of the sigmoid to form 
the circumferential longitudinal muscle of the rectal wall approximately 12 to 15 cm from the dentate line. 
The rectum is defined clinically as the distal large intestine commencing opposite the sacral promontory 
and ending at the anorectal ring, which corresponds to the proximal border of the puborectalis muscle 
palpable on digital rectal examination. When measuring below with a rigid sigmoidoscope, it extends 16 
cm from the anal verge.” (CAP Guidelines, p. 15-16, 2012).  
7. Was this procedure performed for Rectal Cancer?: 
-Yes/No 
8. Was this procedure performed with curative intent?  
-Yes/No 
Mesorectal Excision:  
The definition of various types of mesorectal excision, as provided by the College of 
American Pathologists is as follows:  
 
Incomplete 
-Little bulk to the mesorectum 
-Defects in the mesorectum down to the muscularis propria 
-After transverse sectioning, the circumferential margin appears very irregular 
Nearly Complete 
-Moderate bulk to the mesorectum 
-Irregularity of the mesorectal surface with defects greater than 5 mm, but none 
extending to the muscularis propria 
-No areas of visibility of the muscularis propria except at the insertion site of the levator 
ani muscles 
Complete 
-Intact bulky mesorectum with a smooth surface 
-Only minor irregularities of the mesorectal surface 
-No surface defects greater than 5 mm in depth 
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-No coning towards the distal margin of the specimen 
-After transverse sectioning, the circumferential margin appears smooth 
 
9. Based on the guidelines above, would you classify this resection as:  
i. Incomplete 
ii. Nearly complete 
iii. Complete 
10. Where there any factors that made the total mesorectal excision more difficult? If so, what 
factors made the TME more difficult?  
- 
11. Where there any factors that made the total mesorectal excision less difficult? If so, what 
factors made the TME less difficult?  
-  
 
 
 
 
 
 
 
 
 
 
 
 
Guidelines from CAP, p. 19, 2012: 
http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2013/Colon_13protocol_3300.pdf 
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Study Title: Evaluation of Rectal Surgery with respect to 
Total Mesorectal Excision in Saskatchewan 
Principle Investigators:  Dr. Gary Groot (Department of General Surgery: Saskatoon).  
   Dr. Julie Kickbush (General Surgery Resident: Saskatoon).  
 
Patient Data Collection Form: 
Personal Information: 
1. Identification Code: 
2. Sex: 
i. Male 
ii. Female 
3. Age at time of procedure: 
Medical History: 
4. Past Medical History: 
i. Oncologic history: 
1. Type  
2. Date of diagnosis:  
ii. Diabetes 
iii. Hypertension 
iv. Obesity 
v. Other: 
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5. Past Surgical History: 
i. Bowel surgeries 
1. Appendectomy  
2. Previous bowel resections 
ii. Abdominal surgeries 
1. Cholecystectomy 
2. Hysterectomy 
iii. Other: 
6. Body Mass Index: 
i. Height 
ii. Weight 
Oncologic History: 
7. Preoperative Chemotherapy: 
i. Yes/No: 
ii. Date:  
iii. Type: 
iv. Cycles: 
8. Preoperative Radiotherapy 
i. Yes/No: 
ii. Date:  
iii. Amount: 
iv. Number of Treatments: 
Surgical Information: 
9. Hospital Site Code: 
10. Surgeon Identification Code: 
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11. Date of procedure: 
i. Day: 
ii. Month: 
iii. Year: 
12. Procedure Performed: 
i. Open/ Laparoscopic/ Laparoscopic Assisted/ Other (e.g. Transanal excision)  
13. Complications: 
14. Estimated Blood Loss: 
Pathology Results: 
15. Preoperative pathology: 
i. Biopsy type: 
ii. Date: 
iii. Pathology result: 
16. Post-operative pathology: 
i. Final diagnosis: 
ii. Tumor Location: 
a. Distance from peritoneal reflection: 
b. Distance from anal verge: 
iii. Tumour Size: 
a. Greatest Dimension:  
b. Additional Dimensions: 
iv. T-stage 
a. T-stage: 
v. N-stage 
a. N-stage: 
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b. Number of lymph nodes sampled: 
c. Number of lymph nodes involved: 
vi. M-stage 
a. M-stage:  
vii. Total Mesorectal Classification: 
a. Complete 
b. Nearly complete 
c. Incomplete 
d. Cannot be determined 
viii. Margins:  
a. Closest Margin: 
i. Distance of invasive carcinoma from closest margin 
ii. Location 
b. Proximal Margin: 
i. Cannot be assessed/ Uninvolved by invasive 
carcinoma/ Involved by invasive carcinoma 
c. Distal Margin: 
i. Cannot be assessed/ Uninvolved by invasive 
carcinoma/ Involved by invasive carcinoma 
d. Circumferential Margin 
i. Cannot be assessed/ Uninvolved by invasive 
carcinoma/ Involved by invasive carcinoma 
e. Deep Margin: 
i. Cannot be assessed/ Uninvolved by invasive 
carcinoma/ Involved by invasive carcinoma 
f. Mucosal Margin: 
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i. Cannot be assessed/ Uninvolved by invasive 
carcinoma/ Involved by invasive carcinoma 
ix. Histologic Type:  
a. Adenocarcinoma 
b. Squamous cell carcinoma 
c. Other: 
x. Histologic Grade: 
a. Not applicable 
b. Cannot be determined 
c. Low-grade (well differentiated to moderately differentiated) 
d. High-grade (poorly differentiated to undifferentiated) 
xi. Microscopic Tumour Extension: 
a. No invasion into lamina propria 
b. Intramucosal carcinoma, invasion of lamina 
propria/muscularis mucosae 
xii. Lymphovascular invasion:  
a. Not identified 
b. Present 
c. Indeterminate 
xiii. Perineural Invasion:  
a. Not identified 
b. Present 
c. Indeterminate 
xiv. Type of Polyp in Which Invasive Adenocarcinoma Arose:  
a. Tubular Adenoma 
b. Villous Adenoma 
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c. Tubulovillous Adenoma 
d. Traditional Serrated Adenoma 
e. Sessile Serrated Adenoma 
f. Hamartomatous Polyp 
g. Indeterminate 
h. Other 
xv. Ancillary Studies:  
a. Special Stains/results:  
b. Microsatellite instability: 
c. Immunohistochemistry for mismatch repair proteins: 
d. Mutational analysis:  
xvi. Treatment Effect: 
a. No prior treatment 
b. Present 
1. No residual tumour 
2. Moderate response 
3. Minimal response 
c. No definite response identified 
d. Not known 
 
